ATE463502T1 - Menschliche toll-homologe - Google Patents

Menschliche toll-homologe

Info

Publication number
ATE463502T1
ATE463502T1 AT07020354T AT07020354T ATE463502T1 AT E463502 T1 ATE463502 T1 AT E463502T1 AT 07020354 T AT07020354 T AT 07020354T AT 07020354 T AT07020354 T AT 07020354T AT E463502 T1 ATE463502 T1 AT E463502T1
Authority
AT
Austria
Prior art keywords
human toll
pro286
pro285
toll homologue
pro358
Prior art date
Application number
AT07020354T
Other languages
English (en)
Inventor
Audrey Goddard
Paul Godowski
Austin Gurney
Melanie Mark
Ruey-Bing Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27535565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE463502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE463502T1 publication Critical patent/ATE463502T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT07020354T 1997-10-17 1998-10-07 Menschliche toll-homologe ATE463502T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6225097P 1997-10-17 1997-10-17
US6531197P 1997-11-13 1997-11-13
US8332298P 1998-04-28 1998-04-28
US10541398A 1998-06-26 1998-06-26
US9086398P 1998-06-26 1998-06-26

Publications (1)

Publication Number Publication Date
ATE463502T1 true ATE463502T1 (de) 2010-04-15

Family

ID=27535565

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98953294T ATE314471T1 (de) 1997-10-17 1998-10-07 Menschliche toll homologen
AT05023238T ATE381574T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe
AT07020354T ATE463502T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT98953294T ATE314471T1 (de) 1997-10-17 1998-10-07 Menschliche toll homologen
AT05023238T ATE381574T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe

Country Status (11)

Country Link
EP (3) EP1887014B1 (de)
JP (3) JP4319348B2 (de)
AT (3) ATE314471T1 (de)
AU (1) AU1070399A (de)
CA (1) CA2305385C (de)
DE (3) DE69841607D1 (de)
DK (3) DK1025227T3 (de)
ES (2) ES2298905T3 (de)
IL (4) IL135345A0 (de)
PT (2) PT1650219E (de)
WO (1) WO1999020756A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696327B1 (en) 1997-10-17 2010-04-13 Genentech, Inc. Antibodies to human Toll homologues
AU2001264889B2 (en) * 1997-05-07 2006-06-29 Schering Corporation Human receptor proteins; related reagents and methods
CN101486759A (zh) * 1997-05-07 2009-07-22 先灵公司 人Toll样受体蛋白、相关试剂和方法
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
CN1721443A (zh) * 2000-05-25 2006-01-18 先灵公司 人受体蛋白；相关的试剂和方法
CA2419894A1 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Process for high throughput screening of cpg-based immuno-agonist/antagonist
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1293566A1 (de) * 2001-09-17 2003-03-19 Societe Des Produits Nestle S.A. Ein löslicher Toll-ähnlicher Rezeptor
KR20040099418A (ko) * 2002-04-08 2004-11-26 다케다 야쿠힌 고교 가부시키가이샤 중증 패혈증 예방 치료제
EP1575548B1 (de) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
CA2505843A1 (en) 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
EP1567863A4 (de) * 2002-11-22 2007-10-03 Nuvelo Inc Therapie- und diagnoseverfahren
WO2004094671A2 (en) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
US8906363B2 (en) * 2003-05-16 2014-12-09 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4562123B2 (ja) * 2003-06-17 2010-10-13 明治乳業株式会社 Ｔｏｌｌ様レセプター強制発現細胞の利用
WO2005001116A1 (ja) * 2003-06-17 2005-01-06 Meiji Dairies Corporation Toll様レセプター強制発現細胞の利用
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
WO2005112986A2 (en) 2004-05-18 2005-12-01 Acorda Therapeutics, Inc. Purifying chondroitinase and stable formulations thereof
JP2008500064A (ja) * 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用
EP1869463A4 (de) 2005-04-15 2010-05-05 Becton Dickinson Co Sepsisdiagnose
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
JP5199878B2 (ja) * 2005-10-27 2013-05-15 セントカー・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター、方法および用途
JP2009536022A (ja) * 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
EP2079835B1 (de) 2006-10-10 2014-03-26 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung von chondroitinase-abci-mutanten
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
MY163936A (en) 2010-01-27 2017-11-15 Takeda Pharmaceuticals Co Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CN101486759A (zh) * 1997-05-07 2009-07-22 先灵公司 人Toll样受体蛋白、相关试剂和方法
ES2263865T3 (es) * 1998-03-25 2006-12-16 Genentech, Inc. Homologo humano de neurotrimina.

Also Published As

Publication number Publication date
DK1887014T3 (da) 2010-08-02
CA2305385A1 (en) 1999-04-29
AU1070399A (en) 1999-05-10
DE69838888T2 (de) 2008-12-11
IL180967A (en) 2012-09-24
EP1887014B1 (de) 2010-04-07
EP1650219A1 (de) 2006-04-26
CA2305385C (en) 2013-05-21
WO1999020756A2 (en) 1999-04-29
DE69833014D1 (de) 2006-02-02
EP1025227B1 (de) 2005-12-28
JP2009131265A (ja) 2009-06-18
ES2343210T3 (es) 2010-07-26
IL221367A (en) 2015-06-30
JP2012105662A (ja) 2012-06-07
JP5425244B2 (ja) 2014-02-26
EP1887014A1 (de) 2008-02-13
JP4319348B2 (ja) 2009-08-26
PT1650219E (pt) 2008-03-31
JP2002526028A (ja) 2002-08-20
EP1025227A2 (de) 2000-08-09
JP5027105B2 (ja) 2012-09-19
ATE314471T1 (de) 2006-01-15
IL135345A (en) 2007-06-03
IL135345A0 (en) 2001-05-20
DK1650219T3 (da) 2008-05-05
DK1025227T3 (da) 2006-05-01
DE69841607D1 (de) 2010-05-20
ATE381574T1 (de) 2008-01-15
DE69833014T2 (de) 2006-08-10
WO1999020756A3 (en) 1999-09-10
ES2298905T3 (es) 2008-05-16
PT1887014E (pt) 2010-07-05
EP1650219B1 (de) 2007-12-19
IL180967A0 (en) 2007-07-04
DE69838888D1 (de) 2008-01-31

Similar Documents

Publication Publication Date Title
ATE381574T1 (de) Menschliche toll-homologe
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
IL131016A0 (en) Selection of proteins using rna-protein fusions
ATE329028T1 (de) Nl3 tie rezeptortyrosinekinase ligandhomologe
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
DE69839444D1 (de) Smad 6 und dessen anwendungen
BG104149A (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
WO2000020449A3 (en) MODIFIED TGF-β SUPERFAMILY PROTEINS
PT868519E (pt) Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
DE69535274D1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
WO1995024481A3 (en) Humanized monoclonal antibodies against human interleukin-4
EP0677115A4 (de) Tia-1 bindendes protein und dafür kodierende, isolierte und komplementäre dna.
EP0816498A3 (de) Exzitatorische Aminosäure Rezeptor-Protein und verwante Nukleinsäure
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
DE59712604D1 (de) Mittel zur identifizierung und therapie metastasierender tumore
WO2001021794A3 (en) Smad associating polypeptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1887014

Country of ref document: EP